Biblio
2023
Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, Clarke JM, Araujo D, Blumenschein GR, Kebriaei P, et al. Autologous T cell therapy for MAGE-A4 solid cancers in HLA-A*02 patients: a phase 1 trial. Nat Med. 2023.
de Langen AJohannes, Johnson ML, Mazières J, Dingemans A-MC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS mutation: a randomised, open-label, phase 3 trial. Lancet. 2023.
2022
Cho BChul, Abreu DRodriguez, Hussein M, Cobo M, Patel AJ, Secen N, Lee KHyeong, Massuti B, Hiret S, Yang JChih Hsin, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022.